Immuno Lab · DeCure for X
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for Marinesco-Sjogren syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for marinesco-sjogren syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
SIL1 nucleotide exchange factor (SIL1) — SIL1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 8Q7R · 3.71 Å · ligand 5-azanyl-1-oxidanyl-pentan-2-one (U9O). Experimental structure, not a prediction.
The inherited abnormality of Marinesco-Sjögren syndrome is not known. Four patients from two families and ethnic groups showed numerous abnormally enlarged lysosomes containing whorled lamellar or amorphous inclusion bodies on electron microscopy, but enzyme studies excluded previously described lysosomal storage disorders. Mutations in the human SIL1 gene and disruption of the murine Sil1 gene, encoding the ER co-chaperone Sil1, were identified as a major cause of MSS and of the “woozy”-mouse phenotype, respectively. The “woozy” mouse is described as a broad phenocopy of human MSS.
Two affected brothers in a Bedouin family showed primarily myopathic changes on electrophysiological studies, while sural nerve biopsy revealed segmental demyelination and axonal degeneration. Both patients had abnormally short lateral third metatarsals, a feature not present in healthy family members, and the authors suggest this should be considered part of the syndrome profile. No drug intervention is mentioned in any of these reports.
One abstract describes a low-dose continuous infusion tolerated by all patients, with 88% receiving the full dose of 0.25 mg. Benefit was identified in 68% of patients with RP or vasculitis but only 25% with PVD. This abstract concerns Sjögren’s syndrome and other connective tissue disorders, not Marinesco-Sjögren syndrome, and no drug name is given. No clinical trial data, survival statistics, or response rates for any drug in Marinesco-Sjögren syndrome exist in these abstracts. What is still missing is any funded trial designed for MSS, any patient stratification by SIL1 mutation status, and any pharmacological intervention tested in this population.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThe inherited abnormality of the Marinesco-Sjögren syndrome is not known. We studied four patients from two different families and ethnic groups. Electron microscopic studies revealed numerous, abnormally enlarged lysosomes that contained whorled lamellar or amorphous inclusion bodies. Enzyme studies excluded previously described lysosomal storage disorders.
https://doi.org/10.1212/wnl.35.3.415AbstractMarinesco-Sjögren syndrome is rarely reported in the Middle East. This is the 2nd report of Marinesco-Sjögren syndrome in an Arab family. The clinical features of 2 affected brothers are described. Electrophysiological studies of the 2 patients showed primarily myopathic changes, whereas sural nerve biopsy revealed segmental demyelination and axonal degeneration. The role of tissue biopsy and the relationship to different electrophysiological studies are discussed. Both patients were noticed to have abnormally short lateral 3 metatarsals, a feature not present in other healthy members of the family. We suggest that this feature should be considered part of the syndrome profile.
https://doi.org/10.1111/j.1600-0404.1997.tb00303.xAbstractMarinesco-Sjögren syndrome (MSS) is a rare autosomal recessive disorder characterized by cerebellar ataxia, congenital cataracts, mental retardation, primary hypogonadism, skeletal abnormalities and myopathy, and patients with MSS are considered to be at risk of falls and bone fractures. We report a patient with MSS who received testosterone replacement therapy and risedronate administration. Muscle strength and the MRI features of the skeletal muscles were not changed, but low bone mass was improved by these treatments, and improvement has continued after risedronate treatment alone. This case suggests that treatment of MSS-related low bone mass using bisphosphonates is likely beneficial.
https://doi.org/10.2169/internalmedicine.50.4206AbstractFriday, 22 April 2005 i133 lowed accepted practice in all but 1 case. The low dose continuous infusion was tolerated by all with 88% receiving the full dose of 0.25mg. Benefit was identified in 68% of patients with RP or vasculitis but only 25% with PVD Sjogren's syndrome and other connective tissue disorders 330.
https://doi.org/10.1093/rheumatology/44.suppl_1.i133AbstractMutations in the humanSIL1gene and disruption of the murineSil1gene, both encoding the endoplasmic reticulum (ER) resident co-chaperone Sil1, were identified as a major cause of MSS and of the “woozy”-mouse phenotype, respectively. Marinesco-Sjögren syndrome (MSS) is a rare progressive[for full text, please go to the a.m. URL]
https://doi.org/10.3205/12dgnn023Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
